Verastem reports phase 2 long-term follow-up data for duvelisib in patients
Verastem announced long-term follow-up data from the DYNAMO™ study, which met its primary endpoint of Overall Response Rate at the final analysis. DYNAMO is a Phase 2 clinical study evaluating duvelisib in patients with indolent non-Hodgkin lymphoma. June 24, 2017